Vermillion (VRML) Reports Q4 Loss of $0.11/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Vermillion Reports Fourth Quarter and Full Year 2014 Results
March 25, 2015 8:01 AM EDTAUSTIN, Texas, March 25, 2015 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, reported on its results for the fourth quarter ended and full year ended December 31, 2014.
"We are very pleased to have completed our new commercial agreement with Quest Diagnostics as well as increase the market in which we offer ASPiRA Labs' OVA1 testing service," stated Valerie Palmieri, President and CEO of Vermillion, Inc.
Key 2015 Developments
March 11- Executed a new business relationship with Quest Diagnostics whereby all OVA1... More